FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3194279895> ?p ?o ?g. }

• W3194279895 endingPage "2866" @default.
• W3194279895 startingPage "2863" @default.
• W3194279895 abstract "Long-acting lipoglycopeptides are promising therapeutic options in Staphylococcus aureus bone and joint infections (BJIs). This study evaluated the ability of dalbavancin to eradicate the intraosteoblastic reservoir of S. aureus, associated with BJI chronicity.Osteoblastic cells were infected with a standardized inoculum of the S. aureus reference strain HG001 and incubated for 24 h with dalbavancin, vancomycin or rifampicin using the MIC, 10×MIC, 100×MIC and/or the intraosseous concentrations reached using standard therapeutic doses (i.e. vancomycin, 10 mg/L; rifampicin, 2 mg/L; and dalbavancin, 6 mg/L). The remaining intracellular bacteria were quantified by plating cell lysates.MICs of dalbavancin, vancomycin and rifampicin were 0.125, 1 and 0.004 mg/L, respectively. Dalbavancin significantly reduced the intracellular inoculum of S. aureus starting at a concentration equal to the MIC, with a significant dose effect, ranging from a reduction of 31.4% (95% CI = 17.6%-45.2%) at MIC to 51.6% (95% CI = 39.8%-63.4%) at 100×MIC compared with untreated cells. Of note, dalbavancin was the only molecule to significantly reduce the intraosteoblastic inoculum at low concentration (MIC). At intraosseous concentrations, dalbavancin reduced the intracellular inoculum by 49.6% (95% CI = 45.1%-54.1%) compared with untreated cells (P < 0.001), with no significant difference compared with vancomycin (38.1%; 95% CI = 19.2%-57.0%; P = 0.646), and was less efficient than rifampicin (69.0%; 95% CI = 63.2-74.8; P < 0.001).Dalbavancin was able to decrease the intraosteoblastic S. aureus inoculum by 50% at intraosseous concentrations reached during standard human therapeutic dosing, with no difference compared with vancomycin, and remained less efficient than rifampicin. However, it was the only molecule significantly active at low concentration." @default.
• W3194279895 created "2021-08-30" @default.
• W3194279895 creator A5002293322 @default.
• W3194279895 creator A5005016980 @default.
• W3194279895 creator A5006224028 @default.
• W3194279895 creator A5008714713 @default.
• W3194279895 creator A5008782369 @default.
• W3194279895 creator A5010401754 @default.
• W3194279895 creator A5012856690 @default.
• W3194279895 creator A5015695784 @default.
• W3194279895 creator A5015766311 @default.
• W3194279895 creator A5018967088 @default.
• W3194279895 creator A5018969643 @default.
• W3194279895 creator A5020133389 @default.
• W3194279895 creator A5020778242 @default.
• W3194279895 creator A5022548057 @default.
• W3194279895 creator A5024694820 @default.
• W3194279895 creator A5026501459 @default.
• W3194279895 creator A5026713810 @default.
• W3194279895 creator A5029450926 @default.
• W3194279895 creator A5029491648 @default.
• W3194279895 creator A5030725109 @default.
• W3194279895 creator A5030906211 @default.
• W3194279895 creator A5031466937 @default.
• W3194279895 creator A5032910149 @default.
• W3194279895 creator A5033382349 @default.
• W3194279895 creator A5036593225 @default.
• W3194279895 creator A5043873680 @default.
• W3194279895 creator A5046235626 @default.
• W3194279895 creator A5047646708 @default.
• W3194279895 creator A5048512498 @default.
• W3194279895 creator A5048881736 @default.
• W3194279895 creator A5049641705 @default.
• W3194279895 creator A5050394932 @default.
• W3194279895 creator A5050558997 @default.
• W3194279895 creator A5050579501 @default.
• W3194279895 creator A5050836379 @default.
• W3194279895 creator A5052869747 @default.
• W3194279895 creator A5053856107 @default.
• W3194279895 creator A5055236354 @default.
• W3194279895 creator A5055753704 @default.
• W3194279895 creator A5056218734 @default.
• W3194279895 creator A5057355995 @default.
• W3194279895 creator A5058113862 @default.
• W3194279895 creator A5060944412 @default.
• W3194279895 creator A5062131508 @default.
• W3194279895 creator A5063696310 @default.
• W3194279895 creator A5064668101 @default.
• W3194279895 creator A5065314587 @default.
• W3194279895 creator A5066342776 @default.
• W3194279895 creator A5067674374 @default.
• W3194279895 creator A5068032148 @default.
• W3194279895 creator A5068858248 @default.
• W3194279895 creator A5069061364 @default.
• W3194279895 creator A5072657381 @default.
• W3194279895 creator A5074241800 @default.
• W3194279895 creator A5075355328 @default.
• W3194279895 creator A5075464822 @default.
• W3194279895 creator A5076657860 @default.
• W3194279895 creator A5078080640 @default.
• W3194279895 creator A5080197522 @default.
• W3194279895 creator A5080776692 @default.
• W3194279895 creator A5081325518 @default.
• W3194279895 creator A5085906670 @default.
• W3194279895 creator A5087054807 @default.
• W3194279895 creator A5089934765 @default.
• W3194279895 creator A5091842926 @default.
• W3194279895 date "2021-08-23" @default.
• W3194279895 modified "2023-10-15" @default.
• W3194279895 title "Evaluation of intraosteoblastic activity of dalbavancin against <i>Staphylococcus aureus</i> in an <i>ex vivo</i> model of bone cell infection" @default.
• W3194279895 cites W1679518507 @default.
• W3194279895 cites W1833757183 @default.
• W3194279895 cites W2064809559 @default.
• W3194279895 cites W2104471465 @default.
• W3194279895 cites W2142067742 @default.
• W3194279895 cites W2157817566 @default.
• W3194279895 cites W2165773062 @default.
• W3194279895 cites W2181985494 @default.
• W3194279895 cites W2206942156 @default.
• W3194279895 cites W2351092296 @default.
• W3194279895 cites W2750783432 @default.
• W3194279895 cites W2777806867 @default.
• W3194279895 cites W2808910184 @default.
• W3194279895 cites W2811370978 @default.
• W3194279895 cites W2903592374 @default.
• W3194279895 cites W2904408893 @default.
• W3194279895 cites W2914625246 @default.
• W3194279895 cites W2921632383 @default.
• W3194279895 cites W2965925000 @default.
• W3194279895 cites W2981214425 @default.
• W3194279895 doi "https://doi.org/10.1093/jac/dkab299" @default.
• W3194279895 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34423360" @default.
• W3194279895 hasPublicationYear "2021" @default.
• W3194279895 type Work @default.
• W3194279895 sameAs 3194279895 @default.
• W3194279895 citedByCount "3" @default.
• W3194279895 countsByYear W31942798952023 @default.
• W3194279895 crossrefType "journal-article" @default.

• next